Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EVMN

Evommune Inc

Dec 22 • 10:11AM ET

16.96

-1.29 -7.07 %

Healthcare • Biotechnology • USA • NYSE

Dec 19, 6:30 PMNo clear company-specific catalyst identified for EVMN's sharp intraday surge during regular trading hours on December 19, 2025.

Held by: VTI VXF VTWO VTWG ACSG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	45.80%	Shs Outstand	31.52M	Perf Week	-3.80%
Market Cap	534.64M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	17.09M	Perf Month	-9.35%
Enterprise Value	716.35M	PEG	-	EPS next Q	-0.97	Inst Own	12.84%	Short Float	0.65%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	8.85%	Short Ratio	0.48	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.11M	Perf YTD	-16.16%
Book/sh	-5.81	P/C	7.03	EPS next 5Y	-	ROE	-	52W High	24.03 -29.42%	Perf Year	-
Cash/sh	2.41	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	13.89 22.15%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.82% 11.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.12	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.76	EPS Q/Q	56.54%	SMA20	-10.38%	Beta	-	Target Price	39.33
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-10.78%	Rel Volume	0.52	Prev Close	18.25
Employees	41	LT Debt/Eq	-	Earnings	Dec 11 AMC	SMA200	-10.78%	Avg Volume	230.86K	Price	16.96
IPO	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-32.71% 200.00%	Trades		Volume	18,126	Change	-7.07%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Initiated	William Blair	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight	$36
Dec-01-25	Initiated	Leerink Partners	Outperform	$42
Dec-01-25	Initiated	Evercore ISI	Outperform	$40
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight

Dec-11-25 04:05PM	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -8.53%
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopfner Robert Lorne	Director	Dec 19 '25	Buy	17.35	1,000	17,350	4,026	Dec 22 07:07 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVMN

Evommune Inc

Upgrade your FINVIZ experience